文献速递关节外科

鼻内右美托咪定减少全麻下全膝关节置换术患者的术后阿片类药物需求

Intranasal Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Total Knee Arthroplasty Under General Anesthesia.
PubMed 文献 · J Arthroplasty · 2020-09-25

回顾性研究纳入150例ASA 1-2级、35-80岁择期单侧初次全膝关节置换术患者,比较麻醉诱导后鼻内给予100 μg右美托咪定与常规处理对术后阿片类药物需求的影响。右美托咪定组累积术后阿片类药物消耗显著减少(-28.5 mg,95%CI 12-47 mg,P < .001),住院时间更短(P < .001),术后平均动脉压和心率更低(P < .001),术后恶心呕吐发生率两组无差异(P = .64)。

要点

  • 鼻内右美托咪定组累积术后阿片类药物消耗较对照组减少28.5 mg(95%CI 12-47 mg,P < .001)。
  • 右美托咪定组住院时间更短(P < .001),术后平均动脉压和心率更低(P < .001)。
  • 两组术后恶心呕吐发生率无显著差异(P = .64)。

核心结论

  • 术中给予鼻内右美托咪定可减少全麻下全膝关节置换术患者的术后阿片类药物消耗,并可能与更短的住院时间相关。

研究设计与样本

  • 回顾性研究纳入150例ASA 1-2级、年龄35-80岁、在全静脉麻醉下接受单侧初次全膝关节置换术的患者。
  • 半数患者在麻醉诱导后接受100 μg鼻内右美托咪定,其余患者接受常规处理。
  • 术后阿片类药物需求以吗啡等效剂量计算,并评估右美托咪定对术后血流动力学、住院时间和术后恶心呕吐发生率的影响。

主要发现

  • 右美托咪定组累积术后阿片类药物消耗较对照组显著减少(-28.5 mg,95%CI 12-47 mg,P < .001)。
  • 累积阿片类药物剂量在术后2、12、24和36小时组间差异已显著(P < .001)。
  • 右美托咪定组住院时间更短(P < .001)。
  • 右美托咪定组术后平均动脉压和心率较对照组更低(P < .001)。
  • 两组术后恶心呕吐发生率无差异(P = .64)。

关键数值与推荐

  • 右美托咪定组累积术后阿片类药物消耗较对照组减少28.5 mg(95%CI 12-47 mg,P < .001)。
  • 右美托咪定组住院时间较对照组更短(P < .001)。
  • 右美托咪定组术后平均动脉压和心率较对照组更低(P < .001)。
  • 两组术后恶心呕吐发生率无显著差异(P = .64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total knee arthroplasty (TKA) causes severe pain, and strong opioids are commonly used in postoperative analgesia. Dexmedetomidine is a novel alpha-2-adrenoceptor-activating drug indicated for procedural sedation, but previous studies have shown clinically relevant analgesic and antiemetic effects. We evaluated retrospectively the effect of intranasal dexmedetomidine on the postoperative opioid requirement in patients undergoing TKA. METHODS: One hundred and fifty patients with ASA status 1-2, age between 35 and 80 years, and scheduled for unilateral primary TKA under total intravenous anesthesia were included in the study. Half of the patients received 100 μg of intranasal dexmedetomidine after anesthesia induction, while the rest were treated conventionally. The postoperative opioid requirement was calculated as morphine equivalent doses for both groups. The effect of dexmedetomidine on postoperative hemodynamics, length of stay (LOS), and incidence of postoperative nausea and vomiting (PONV), was evaluated. RESULTS: The cumulative postoperative opioid consumption was significantly reduced in the dexmedetomidine group compared to the control group (-28.5 mg, 95% CI 12-47 mg P < .001). The reduction in cumulative opioid dose was significantly different between the groups already at 2, 12, 24, and 36 h postoperatively (P < .001). LOS was shorter in the dexmedetomidine group (P < .001), and the dexmedetomidine group had lower postoperative mean arterial pressure and heart rates were lower compared to the control group (P < .001). The incidence of PONV did not differ between the groups (P = .64). CONCLUSION: Intraoperatively administered intranasal dexmedetomidine reduces postoperative opioid consumption and may be associated with a shorter hospital stay in patients undergoing TKA under general anesthesia.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Seppänen SM, Kuuskoski R, Mäkelä KT, et al. Intranasal Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Total Knee Arthroplasty Under General Anesthesia. J Arthroplasty. 2020. PMID: 33046329. doi:10.1016/j.arth.2020.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。